ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has been approved in Uruguay for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Uruguay is the first country in Latin America to grant JETREA® approval.
ThromboGenics' partner Alcon, which is commercializing JETREA® outside the US, will be responsible for the launch of the drug in Uruguay.
JETREA® is the first in class pharmacological treatment for this indication and was approved by the European Commission in the European Union in March 2013.
Dr Patrik De Haes, CEO of ThromboGenics, says: "The approval of JETREA® in Uruguay, its first in Latin America, is an important further step in expanding access to JETREA® globally. We look forward to its launch and believe it will become a first-line treatment for earlier treatment of VMT patients in Latin America."